A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors

It is well known that tumor necrosis factor-related apoptosis inducing ligand receptor 1 or 2 (DR4/DR5) is specifically expressed in various tumor cells, but less or no expression in most normal cells. Many first generations of TRAIL agonists including recombinant preparations of TRAIL, agonistic an...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shuyong, Zheng, Chao, Zhu, Wan, Xiong, Peng, Zhou, Dongdong, Huang, Changjiang, Zheng, Dexian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691585/
https://www.ncbi.nlm.nih.gov/pubmed/31410224
http://dx.doi.org/10.7150/thno.33598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691585/
https://www.ncbi.nlm.nih.gov/pubmed/31410224
http://dx.doi.org/10.7150/thno.33598

Ejemplares similares